title: Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy--a randomized, double-blind, placebo-controlled multicentre trial.
abstract: BACKGROUND
  An association between Helicobacter pylori infection and lymphocytic gastritis has been postulated.
  
  
  OBJECTIVE
  To assess the long-term effect of H. pylori eradication therapy on lymphocytic gastritis in a double-blind, placebo-controlled, multicentre trial.
  
  
  METHODS
  Patients with lymphocytic gastritis were randomized to receive either 1-week triple therapy for eradication of H. pylori or omeprazole plus placebo. Endoscopy and histology was performed at baseline and after 3 and 12 months. Patients of the omeprazole/placebo group with persistent lymphocytic gastritis after 12 months received crossover open-label triple therapy.
  
  
  RESULTS
  Fifty-one patients were randomized. Intention-to-treat analysis revealed a trend to a higher healing rate of lymphocytic gastritis 3 months after triple therapy compared with omeprazole/placebo (83.3% vs. 57.7%, 95% CI for RR: 0.8-2.8, P = 0.06). After 12 months, the healing rate of lymphocytic gastritis was significantly higher after triple therapy compared with omeprazole/placebo (intention-to-treat 95.8% vs. 53.8%, 95% CI for RR: 1.1-3.5, P = 0.01). All patients (n = 5) who received crossover triple therapy, showed healing of lymphocytic gastritis after further 12 months.
  
  
  CONCLUSIONS
  Our study demonstrates that 1-week triple therapy aiming at eradication of H. pylori leads to a complete and long-lasting resolution of lymphocytic gastritis in the majority of patients.
authors.affiliation: Medical Department I, Technical University Hospital, Dresden, Germany. ahmed.madisch@uniklinikum-dresden.de
authors.forename: A
authors.initials: A
authors.lastname: Madisch
authors.forename: S
authors.initials: S
authors.lastname: Miehlke
authors.forename: F
authors.initials: F
authors.lastname: Neuber
authors.forename: A
authors.initials: A
authors.lastname: Morgner
authors.forename: E
authors.initials: E
authors.lastname: Kuhlisch
authors.forename: S
authors.initials: S
authors.lastname: Rappel
authors.forename: N
authors.initials: N
authors.lastname: Lehn
authors.forename: E
authors.initials: E
authors.lastname: Bayerdörffer
authors.forename: G
authors.initials: G
authors.lastname: Seitz
authors.forename: M
authors.initials: M
authors.lastname: Stolte
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy* / Q000382:microbiology; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006801:Humans; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole